Wedbush upgrades Replimune Group stock rating on FDA acceptance of BLA
PositiveFinancial Markets

Wedbush has upgraded the stock rating of Replimune Group following the FDA's acceptance of their Biologics License Application (BLA). This is significant as it reflects confidence in Replimune's potential to bring innovative therapies to market, which could enhance investor interest and drive stock performance.
— Curated by the World Pulse Now AI Editorial System